At the Heart of Depression: 3 New Studies

New research brings us closer to learning about the associations between psychological states, quality of life, and cardiovascular health.

Related Videos
Related Content

Positive Results for Lumateperone in Patients With Mixed Features in Major Depressive Disorder, Bipolar Depression

March 29th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Psychopharmacologic Treatment of Bipolar II Depression

March 15th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

Report Reveals More Than 50% of Americans Misuse At-Home Ketamine

March 13th 2023

6 Months of Continuing Medical Education

March 11th 2023

Positive Results for Lumateperone in Patients With Mixed Features in Major Depressive Disorder, Bipolar Depression

March 29th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Psychopharmacologic Treatment of Bipolar II Depression

March 15th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

Report Reveals More Than 50% of Americans Misuse At-Home Ketamine

March 13th 2023

6 Months of Continuing Medical Education

March 11th 2023

Positive Results for Lumateperone in Patients With Mixed Features in Major Depressive Disorder, Bipolar Depression

March 29th 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Psychopharmacologic Treatment of Bipolar II Depression

March 15th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

Report Reveals More Than 50% of Americans Misuse At-Home Ketamine

March 13th 2023

6 Months of Continuing Medical Education

March 11th 2023
© 2023 MJH Life Sciences

All rights reserved.